Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Opthea Limited Sponsored ADR ( (OPT) ) just unveiled an announcement.
Opthea Limited has announced the development of Sozinibercept, a first-in-class VEGF-C/D trap inhibitor designed to be used in combination with standard anti-VEGF-A therapies, aimed at enhancing visual outcomes for patients with wet age-related macular degeneration (AMD). The company anticipates substantial market opportunities, with pivotal trial data expected in 2025, which positions Sozinibercept as a promising asset in a multibillion-dollar market, potentially improving vision for millions and addressing a significant unmet need.
More about Opthea Limited Sponsored ADR
Opthea Limited is a biotechnology company operating in the pharmaceutical industry. The company focuses on developing innovative treatments for eye diseases, particularly age-related macular degeneration (AMD), using its proprietary VEGF-C/D ‘trap’ inhibitor technology.
YTD Price Performance: -4.35%
Average Trading Volume: 22,543
Technical Sentiment Consensus Rating: Hold
Current Market Cap: $567.4M
Find detailed analytics on OPT stock on TipRanks’ Stock Analysis page.
